{
  "query": "regulatory findings company name",
  "timestamp": "2025-09-06 08:05:37",
  "config": {
    "top_k": 5,
    "similarity_threshold": 0.0,
    "reranking_enabled": true,
    "hybrid_search_enabled": true,
    "hybrid_search_weight": 0.7
  },
  "results": [
    {
      "id": 1,
      "text": "e end \nof 2021. The latest revision includes additional \nprinciples on environment protection, respect of \nhuman rights, and anti-corruption matters. In addition to the Code of Conduct, control \nmechanisms are implemented throughout the \norganization to prevent and detect frauds, including \nseparation \nof \nduties, regular \nindependent audits of travel and entertainment \nexpenses, and the availability of a fraud \nreporting procedure. Respect for Ethics is also part of our terms with \nsuppliers of products and services, agents, distributors, and partners (see for example the \nIBA Code of Conduct for Suppliers). Intellectual property risk \nThe Company holds intellectual property rights.",
      "similarity_score": 0.06624434703092372,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 237,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    },
    {
      "id": 2,
      "text": "rt / corporate governance statement \n2-13 \nDelegation of responsibility for managing \nimpacts \np58 AR2023 Management report / corporate governance statement \n2-14 \nRole of the highest governance body in \nsustainability reporting \np65 AR2023 Management report / corporate governance statement / sustainability \nboard meeting \n2-15 \nConflicts of interest \np57 AR2023 Management report / corporate governance statement / conflict of \ninterest \n2-16 \nCommunication of critical concerns \np51 AR2023 Management report / principal risks and uncertainties faced by the \ncompany \np80 AR2023 Management report",
      "similarity_score": 0.06859501479471457,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 1049,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    },
    {
      "id": 3,
      "text": "3-1 \nManagement of material topics \np34 AR2023 A committed company / employees \n405-1 \nDiversity of governance bodies and \nemployees \np66 AR2023 Management report / corporate governance statement / diversity, equity and inclusion policy \np194 AR2023 GRI appendix 405-1 / diversity of employees \n405-2 \nRatio of basic salary and remuneration of \nwomen to men \np80 AR2023 Management report / corporate governance statement / codes of \nconduct \nGRI 414 SUPPLIER SOCIAL ASSESSMENT v2016",
      "similarity_score": 0.07664848376683235,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 1070,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    },
    {
      "id": 4,
      "text": "ich is \ndeemed most appropriate by the individual on \nwhom such minimum is imposed, including \nthrough the Long-Term Incentive plan described \nabove. The MHR is applicable during the entire period \nof the contractual relationship with IBA, and \nduring a three year period starting at the date the \nsaid contractual relationship terminates unless \nthe termination of the contractual relationship is \nconsecutive to the retirement or death of the \nconcerned Executive. The Managing Directors are significant owners \nof the reference shareholder and comply with the \nMHR provision.",
      "similarity_score": 0.05342277806739919,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 368,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    },
    {
      "id": 5,
      "text": "onformalFLASH6 technology. This builds on \nthe existing relationship between IBA and \nKUMC, who had previously published a joint \nabstract on FLASH technology together during \nthe \nProton \nTherapy \nCo-Operative \nGroup \n(PTCOG) Congress in June 2023. Earlier in \n2023, IBA also announced the first FLASH \nresearch project on a ProteusONE in a clinical \nsetting, with PARTICLE, the proton therapy \ncenter in Leuven, Belgium. IBA also continues to \ndevelop Proton ARC Therapy and completed a \ncomprehensive integration test at the Proton \nTherapy Center of William Beaumont Hospital in \nMichigan, US, at",
      "similarity_score": 0.05828877499494059,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 199,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    }
  ]
}